Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuelei Shen

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Antibody Therapeutics|August 5, 2022
Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspectiveMengyu Li, Sen Mei, Yi Yang, et al.
Investigational New Drugs|February 21, 2025
A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCsHuoying Huang, Yuxin Zhou, Chengzhang Shang, et al.
Immunity|October 13, 2009
How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic isletsMarkus Feuerer, Yuelei Shen, Dan R Littman, et al.
Journal of Leukocyte Biology|March 30, 2012
Visualization of mucosal homeostasis via single- and multiphoton intravital fluorescence microscopyCassie Xu, Yuelei Shen, Dan R Littman, et al.
Antibody Therapeutics|July 1, 2021
Antibody heavy chain CDR3 length-dependent usage of human IGHJ4 and IGHJ6 germline genesHuimin Wang, Kai Yan, Ruixue Wang, et al.
International Immunopharmacology|January 23, 2023
The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluationXingyan Yu, Tao Li, Zhiyuan Shen, et al.
The Journal of Experimental Medicine|August 30, 2008
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanomaSergio A Quezada, Karl S Peggs, Tyler R Simpson, et al.
Briefings in Bioinformatics|April 1, 2022
A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domainMengya Chai, Yajuan Guo, Liu Yang, et al.
Journal of Toxicologic Pathology|February 28, 2022
Generation of a uniform thymic malignant lymphoma model with C57BL/6J <i>p53</i> gene deficient miceSusu Liu, Jianjun Lyu, Qianqian Li, et al.
Aging and Disease|June 6, 2025
A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug DevelopmentAlex Zhavoronkov, Qian Wang, Yujie Liu, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Antibody Therapeutics|August 5, 2022
Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspectiveMengyu Li, Sen Mei, Yi Yang, et al.
Investigational New Drugs|February 21, 2025
A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCsHuoying Huang, Yuxin Zhou, Chengzhang Shang, et al.
Immunity|October 13, 2009
How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic isletsMarkus Feuerer, Yuelei Shen, Dan R Littman, et al.
Journal of Leukocyte Biology|March 30, 2012
Visualization of mucosal homeostasis via single- and multiphoton intravital fluorescence microscopyCassie Xu, Yuelei Shen, Dan R Littman, et al.
Antibody Therapeutics|July 1, 2021
Antibody heavy chain CDR3 length-dependent usage of human IGHJ4 and IGHJ6 germline genesHuimin Wang, Kai Yan, Ruixue Wang, et al.
International Immunopharmacology|January 23, 2023
The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluationXingyan Yu, Tao Li, Zhiyuan Shen, et al.
The Journal of Experimental Medicine|August 30, 2008
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanomaSergio A Quezada, Karl S Peggs, Tyler R Simpson, et al.
Briefings in Bioinformatics|April 1, 2022
A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domainMengya Chai, Yajuan Guo, Liu Yang, et al.
Journal of Toxicologic Pathology|February 28, 2022
Generation of a uniform thymic malignant lymphoma model with C57BL/6J <i>p53</i> gene deficient miceSusu Liu, Jianjun Lyu, Qianqian Li, et al.
Aging and Disease|June 6, 2025
A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug DevelopmentAlex Zhavoronkov, Qian Wang, Yujie Liu, et al.
Pageof 2